Implementation and outcomes of China's drug patent linkage system: lessons from international experience [0.03%]
中国药品专利链接制度的实施及成效：国际经验借鉴
Yu Chen,Xinjuan Liu,Suju Li et al.
Yu Chen et al.
Introduction: The drug patent linkage system plays a crucial role in achieving a balance between protecting drug innovation and ensuring the accessibility of generic drugs. Currently, this system has been implemented in m...
Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly biosciences inc [0.03%]
评估Assembly Biosciences Inc.的HELQ抑制剂ABI-5366专利组合
Christian Gege,Gerald Kleymann
Christian Gege
Background: Helicase-primase is an interesting target for small molecule therapy of herpes simplex virus (HSV) infections. With amenamevir already approved for varicella-zoster virus and herpes simplex in Japan and with p...
Tao Liu,Mingbo Su,Yuxuan Wang et al.
Tao Liu et al.
Introduction: Checkpoint kinase 1 (CHK1), a serine/threonine kinase, plays an important role in the DNA damage response (DDR), such as cell cycle checkpoints, DNA repair, transcriptional regulation, and apoptosis inhibiti...
Traf2- and Nck-interacting kinase inhibitors: a patent review（2008 - 2024） [0.03%]
有关Traf2和Nck相互作用激酶的抑制剂专利综述（2008-2024）
Luoheng Qin,Vladimir Aladinskiy,David Gennert et al.
Luoheng Qin et al.
Introduction: Traf2- and Nck-interacting kinase (TNIK) is a crucial player in various intracellular signaling pathways, including Wnt/β-catenin, cytoskeleton organization, and immune activation. It phosphorylates several...
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 - present): part 1-patent granted [0.03%]
组蛋白去乙酰化酶抑制剂合理联用治疗癌症的专利点评（2020-至今）：已授权部分
Yugal Kishor Shukla,Vandana,Vivekananda Mandal et al.
Yugal Kishor Shukla et al.
Introduction: Tumor cell heterogeneity poses a challenge to monotherapy, as a single drug cannot kill all heterogeneous cancer cells of a tumor. The surviving cells may develop resistance, potentially leading to tumor rec...
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present) [0.03%]
用于治疗2型糖尿病的GPR120激动剂专利回顾（2020-至今）
Kainat Ilyas,Ismat Nawaz,Kanwal Rehman et al.
Kainat Ilyas et al.
Introduction: Type 2 diabetes mellitus (T2DM) affects over 530 million individuals globally and is projected to reach 783 million by 2045, necessitating novel therapeutic strategies beyond current options. G-protein-coupl...
The potential of bacteriophages in treating multidrug-resistant ESKAPE pathogen infections [0.03%]
噬菌体在治疗耐多药ESKAPE病原感染方面的潜力
Izadora Dillis Faccin,Gleyce Hellen de Almeida de Souza,Jean Carlos Pael Vicente et al.
Izadora Dillis Faccin et al.
Introduction: Antimicrobial resistance (AMR) and the emergence of multidrug-resistant bacteria, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa...
Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019-2024) [0.03%]
关于糖原合酶激酶3β(GSK-3β)抑制剂的专利更新(2019-2024)
Swanand Vinayak Joshi,Devandla Soujanya,Manchella Sai Supriya et al.
Swanand Vinayak Joshi et al.
Introduction: Glycogen synthase kinase-3β (GSK-3β) is a proline-directed serine/threonine kinase identified over 40 years ago. It is the key enzyme involved in glycogen biosynthesis and is expressed in all human tissues...
Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024) [0.03%]
克服EGFR-酪氨酸激酶三联突变体在非小细胞肺癌治疗中的屏障：第四代抑制剂（2017-2024）专利综述
Narendra R Nagpure,Harun M Patel
Narendra R Nagpure
Introduction: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with 'epidermal growth factor receptor (EGFR)' mutations being a primary driver of tumor progression. This review highlights th...
Recent advances in tropomysosin receptor kinase (TRK) inhibitors: a 2023-2024 patent landscape review [0.03%]
2023-2024年神经生长因子受体酪氨酸激酶(TRK)抑制剂专利布局分析进展
Minh Le,Elena Timakova,Ralf Schirrmacher et al.
Minh Le et al.
Introduction: The rise of tissue-agnostic therapies has revolutionized cancer treatment, with therapies targeting NTRK fusions leading the way. TRK inhibitors like larotrectinib and entrectinib marked a paradigm shift - p...